All In Biotech

Drug Trial Radar · NCT07457580

Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)

A Real-World Retrospective Observational Study Characterizing Patients With Stage 2 Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Mar 16, 2026

Primary completion

Nov 30, 2026

Study completion Nov 30, 2026

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Mar 9, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multi-country, multi-center retrospective observational cohort study based on secondary data collected via chart review, with the aim of describing patient characteristics (including relevant comorbidities), monitoring and treatment practices related to Type 1 diabetes mellitus (T1D) progression, and time to T1D progression in participants who received teplizumab as part of Managed Access Programs (MAPs). This study design was chosen in order to gain rapid insight into the current use of teplizumab in clinical practice and the characteristics of patients who received the treatment.

Conditions

  • Type 1 Diabetes

Interventions

  • TeplizumabDrug

    This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participant demographics at teplizumab initiationTime frame: At Day 1 (first dose of teplizumab)
  2. Participants' family history of T1D and autoimmune diseasesTime frame: At Day 1 (first dose of teplizumab)
  3. Presence of T1D susceptibility genesTime frame: At Day 1 (first dose of teplizumab)
  4. Presence of T1D susceptibility genesTime frame: At Day 1 (first dose of teplizumab)
  5. Participants' medical historyTime frame: From 6 months prior to the first dose of teplizumab (teplizumab initiation) (or the earliest date of all data contributing to Stage 2 T1D diagnosis, whichever is earlier) up to medical records abstraction date, approximately 3-4 years

Locations

16 sites in 6 countries. Site status is shown where the registry gives one.

  • Investigational Site Number: 0560001

    Leuven, Belgium · Completed

  • Investigational Site Number: 2500001

    Bron, France · Completed

  • Investigational Site Number: 2500003

    Paris, France · Completed

  • Investigational Site Number: 2500002

    Paris, France · Completed

  • Investigational Site Number: 2760003

    Augsburg, Germany · Recruiting

  • Investigational Site Number: 2760002

    Frankfurt, Germany · Completed

  • Investigational Site Number: 2760001

    Hanover, Germany · Completed

  • Investigational Site Number: 2760004

    Munich, Germany · Recruiting

  • Investigational Site Number: 3800001

    Ancona, Italy · Completed

  • Investigational Site Number: 3800003

    Palermo, Italy · Completed

  • Investigational Site Number: 3800002

    Verona, Italy · Completed

  • Investigational Site Number: 7240001

    Madrid, Spain · Completed

  • Investigational Site Number: 7240002

    Madrid, Spain · Completed

  • Investigational Site Number: 7240003

    Zaragoza, Spain · Completed

  • Investigational Site Number: 8260001

    Birmingham, United Kingdom · Completed

  • Investigational Site Number: 8260002

    London, United Kingdom · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.